Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21581264 | 0.98 | CXCR4 (0.61) | CXCR4SIGMAR1POLBSMN1; SMN2HSD17B10 | |
| SCHEMBL21581271 | 0.98 | CXCR4 (0.61) | CXCR4SIGMAR1POLBSMN1; SMN2HSD17B10 | |
| SCHEMBL1409001 | 0.98 | CXCR4 (0.61) | CXCR4SIGMAR1POLBSMN1; SMN2HSD17B10 | |
| Hydrochloric Acid SCHEMBL6959691 | 0.98 | CXCR4 (0.55) | CXCR4SIGMAR1POLBSMN1; SMN2HSD17B10 | |
| SCHEMBL1408768 | 0.98 | CXCR4 (0.61) | CXCR4SIGMAR1POLBSMN1; SMN2HSD17B10 | |
| SCHEMBL12003 | 0.93 | CXCR4 (0.56) | CXCR4SIGMAR1POLBSMN1; SMN2HSD17B10 | |
| SCHEMBL11443013 | 0.93 | CXCR4 (0.56) | CXCR4SIGMAR1POLBSMN1; SMN2HSD17B10 | |
| SCHEMBL29943537 | 0.91 | CXCR4 (0.54) | CXCR4SIGMAR1POLBSMN1; SMN2HSD17B10 | |
| Piperazine SCHEMBL28092893 | 0.91 | CXCR4 (0.59) | CXCR4SIGMAR1POLBSMN1; SMN2HSD17B10 | |
| SCHEMBL8714265 | 0.91 | CXCR4 (0.59) | CXCR4SIGMAR1POLBSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8771403-B2 | Method and system for capturing carbon dioxide and/or sulfur dioxide from gas stream | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-08 | — | — | US | claimed |
| CN-103221114-A | Method and system for capturing carbon dioxide and/or sulfur dioxide from gas streams | UNIV CALIFORNIA | 2013-07-24 | — | — | CN | claimed |
| WO-2012030630-A1 | METHOD AND SYSTEM FOR CAPTURING CARBON DIOXIDE AND/OR SULFUR DIOXIDE FROM GAS STREAM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-08 | — | — | WO | claimed |
| EP-1802591-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-01-11 | — | — | EP | claimed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | claimed |
| EP-1773860-A4 | METHODS FOR IDENTIFYING RISK OF TYPE II DIABETES AND TREATMENTS THEREOF | SEQUENOM INC (US) | 2009-05-06 | — | — | EP | claimed |
| EP-1528925-B1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | EP | claimed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | claimed |
| US-7501516-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | claimed |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | claimed |
| US-6291455-B1 | PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2001-09-18 | — | — | US | claimed |
| EP-0885198-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-23 | — | — | EP | claimed |
| US-5696268-A | REACTING N-ACYLAMINO ACID DERIVATIVE WITH OPTICALLY ACTIVE ENAMINE DERIVATIVE, REACTING PRODUCT WITH AMMONIA OR AMMONIUM SALT | FUJIREBIO INC. (JP) | 1997-12-09 | — | — | US | claimed |
| WO-1997032856-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-12 | — | — | WO | claimed |
| US-5644059-A | REACTION OF KETONE WITH ACRYLAMIDE AND AMMONIA OR AMMONIUM SALT | FUJIREBIO INC. (JP) | 1997-07-01 | — | — | US | claimed |
| EP-0251905-B1 | Esters of alginic acid | FIDIA SPA (IT) | 1994-11-02 | — | — | EP | claimed |
| EP-0609968-A2 | Compositions comprising partial esters of alginic acid | FIDIA S.p.A. (IT) | 1994-08-10 | — | — | EP | claimed |
| EP-0488345-A1 | 1,4-Dihydropyridine derivatives and methods of producing the same | FUJIREBIO INC. (JP) | 1992-06-03 | — | — | EP | claimed |
| EP-0099148-B1 | PIPERAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | GIST-BROCADES N.V. (NL) | 1988-02-17 | — | — | EP | claimed |
| EP-0251905-A2 | Esters of alginic acid | FIDIA S.p.A. (IT) | 1988-01-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | CXCR4 36/4885SIGMAR1 158/4885POLB 2260/4885 |
| US-20090233924-A1 | Quinazoline derivatives | AQP1, PGF, F12 | CXCR4 21/4885SIGMAR1 183/4885POLB 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.